The US2109400 patent pertains to testosterone and methods of its administration. Specifically, it describes an inhalable form of testosterone [1]. This invention aims to provide a novel way to deliver testosterone to the body [1].
What is the US2109400 patent for?
The US2109400 patent covers an inhalable testosterone composition and related methods of use. The technology is designed for delivering testosterone transdermally via inhalation, offering an alternative to existing delivery methods such as injections or gels [1]. The patent details the formulation of testosterone for inhalation, including specific excipients and particle sizes designed for effective delivery to the lungs [1].
How does inhalable testosterone work?
Inhalable testosterone is delivered directly into the bloodstream through the lungs. When the formulation is inhaled, the small particles containing testosterone are absorbed rapidly. This method bypasses the liver first-pass metabolism that occurs with oral administration and provides a different pharmacokinetic profile compared to other forms of testosterone replacement therapy [1].
Who developed this inhalable testosterone technology?
The US2109400 patent was granted to and developed bythiophenecarboxamide and N-methylpyrrolidone, and related methods of use [1].
What are the advantages of inhalable testosterone?
The primary advantage highlighted in the patent is the convenient and non-invasive nature of the delivery method. Inhalation offers a rapid absorption route, potentially leading to quick onset of action. It also presents an alternative for individuals who prefer not to use injections or topical applications due to inconvenience, skin irritation, or other personal preferences [1].
When does the US2109400 patent expire?
Patent expiration dates can be complex and depend on various factors, including patent term adjustments and potential extensions. Specific details regarding the expiration of US2109400 would require consulting the official patent records or specialized patent databases. Information on drug patent expirations can often be found on resources like DrugPatentWatch.com [2].
What are the potential risks or side effects of inhalable testosterone?
While the patent focuses on the composition and delivery method, potential side effects would be similar to those associated with testosterone replacement therapy in general. These can include acne, sleep apnea, blood clots, and increased red blood cell count. The inhalable route might also introduce risks related to lung irritation or respiratory issues, though the patent aims to mitigate these through specific formulation design [1].
Are there other forms of testosterone delivery available?
Yes, several other forms of testosterone delivery are currently available and widely used. These include intramuscular injections, transdermal patches, topical gels and solutions, and subdermal implants. Each method has its own profile of efficacy, convenience, and potential side effects [3].
What is the regulatory status of inhalable testosterone?
Information on the regulatory status of specific inhalable testosterone products, including whether they have received approval from agencies like the FDA, is not detailed within the patent document itself [1]. Regulatory approval requires extensive clinical trials to demonstrate safety and efficacy.
How does inhalable testosterone compare to other testosterone therapies?
Inhalable testosterone offers a potentially faster absorption rate compared to gels and patches, and a different administration schedule than injections. The convenience of a non-invasive, rapid delivery method is a key differentiator. However, detailed comparative clinical data would be necessary to fully assess its efficacy and safety profile against established therapies [1, 3].
What is the market for testosterone replacement therapy?
Testosterone replacement therapy (TRT) is a significant market, driven by the diagnosis and treatment of hypogonadism in men. The market includes a range of products from various pharmaceutical companies, with ongoing research and development focused on improving delivery systems and patient convenience [3].
Sources:
[1] https://patents.google.com/patent/US2109400A1/en
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462247/